Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial

Chimeric antigen receptor T-cell (CAR-T) therapy yields durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Cytokine release syndrome (CRS) is a CAR-T therapy–related adverse event. To date, clinical trials of different CAR-T products have not been align...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood Adv
Prif Awduron: Schuster, Stephen J., Maziarz, Richard T., Rusch, Elisha S., Li, Junlong, Signorovitch, James E., Romanov, Vadim V., Locke, Frederick L., Maloney, David G.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2020
Pynciau:
Immunobiology and Immunotherapy
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7160283/
https://ncbi.nlm.nih.gov/pubmed/32271899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001304
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg